NCT03638830View on ClinicalTrials.gov

Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa

PHASE2CompletedINTERVENTIONAL
Enrollment

777

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

November 23, 2022

Study Completion Date

November 23, 2022

Conditions
Patients With Complicated Urinary Tract Infections Caused by P. AeruginosaPseudomonas AeruginosaPseudomonas InfectionsUrinary Tract Infections
Interventions
DRUG

Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim

"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)+placebo"

DRUG

Ftortiazinon (tablets 300 mg) full dose + Maxipim

"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)"

OTHER

placebo+Maxipim

placebo

Trial Locations (5)

Unknown

"Road Clinical Hospital of Open Joint Stock Company Russian Railways", Saint Petersburg

"St. Petersburg state budgetary institution of health care City hospital № 26", Saint Petersburg

Baltic Medicine, Saint Petersburg

"Scientific and Research Center Eco-Safety", Saint Petersburg

Vsevolozhsk Clinical Interdistrict Hospital, Vsevolozhsk

Sponsors
All Listed Sponsors
collaborator

Acellena Contract Drug Research and Development

OTHER

lead

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER